"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
Large doses can depress atrioventricular and intraventricular conduction and thereby produce serious arrhythmias.
Last reviewed on RxList: 3/31/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Papaverine Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.